id: limited_ghb_surveillance_to_delayed_clinical_identification
name: Limited Population Surveillance of GHB Distribution â†’ Delayed Clinical Identification
  of GHB Cases
from_node:
  node_id: limited_ghb_surveillance
  node_name: Limited Population Surveillance of GHB Distribution
to_node:
  node_id: delayed_clinical_identification
  node_name: Delayed Clinical Identification of GHB Cases
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Limited information exists about GHB abuse and distribution patterns among
  general population'
- 'Step 2: Lack of surveillance data reduces clinical awareness and suspicion for
  GHB-related presentations'
- 'Step 3: Delayed or missed identification occurs in both acute poisoning and withdrawal
  scenarios'
- 'Step 4: Need for testing in conventional and non-conventional biological matrices
  is not prioritized'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'E. Marinelli et al. 2020. "Gamma-hydroxybutyrate Abuse: Pharmacology
    and Poisoning and Withdrawal Management." *Arhiv za Higijenu Rada i Toksikologiju*.
    https://doi.org/10.2478/aiht-2020-71-3314'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.698469'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/limited_ghb_surveillance_to_delayed_clinical_identification.yaml
_category: healthcare_access
